Lung transplantation has become a valuable and well-accepted treatment option for most end-stage lung diseases. Lung transplant recipients are at risk of transplanted organ rejection, and life-long immunosuppression is necessary. Clear evidence is essential to identify an optimal, safe and effective immunosuppressive treatment strategy for lung transplant recipients. Consensus has not yet been achieved concerning use of immunosuppressive antibodies against T-cells for induction following lung transplantation.
Journal review article
Cochrane Database of Systematic Reviews, 2013, Vol 2013, Issue 11, p. 1-74
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review